|
Post by mannmade on Oct 31, 2018 11:02:58 GMT -5
I just re-listened to the question from Goldman (starts at roughly the 32:00 mark). Rothblatt said: "... during the past quarter, we acquired the exclusive rights to a very exciting product for idiopathic fibrosis which is not associated with PAH."
However, in that answer he also mentions the Samumed deal which would indicate that he was not talking about Samumed initially. So there is a possibility that he is initially talking about a MNKD approach towards IPF with a new version of tobramycin. Remember that tobramycin resides in Box 1 of Mike's pipeline matrix. The fact that Martine mentions this in response to what they are doing outside the scope of PAH correlates well with the description of the $10 million funding in the 10Q: "We also entered into a research agreement for the conduct of research by MannKind for products outside the scope of the licensing and collaboration agreement. MannKind received an initial payment of $10.0 million in consideration for its performance under the research agreement. The $10.0 million payment is included within research and development costs on our consolidated statements of operations for the three and nine months ended September 30, 2018."Q - Unidentified Analyst Is there any preferences with regard to collaboration vis-à-vis additional products as you get rather in license and partner with for specific areas you are focusing. Michael Castagna Yes, there's two areas in particular. So one is lung diseases I’ll say cystic fibrosis, idiopathic pulmonary fibrosis are two ideal ones I look at. In particular if you look at Tobramycin, there is [indiscernible] from Novartis. We think that's a great opportunity in that market to deliver something more effective to the lungs. www.google.com/amp/s/seekingalpha.com/amp/article/4209479-mannkind-corporation-mnkd-ceo-michael-castagna-cantor-fitzgerald-global-healthcare-conferenceIt would be amazing and a bit ironic if mnkd partnered w Novartis for a tsmolecule. Not wanting to speculate but why would Mike mention Novartis unless there is potential for this? Hmmm...
|
|
|
Post by jlaw277 on Oct 31, 2018 11:47:20 GMT -5
|
|
|
Post by mnholdem on Oct 31, 2018 12:02:18 GMT -5
Rothblatt's concluding remarks about the company's future included anticipated growth into the areas of pulmonary fibrosis and small-cell lung cancer.
|
|
|
Post by mango on Oct 31, 2018 12:08:43 GMT -5
It would be amazing and a bit ironic if mnkd partnered w Novartis for a tsmolecule. Not wanting to speculate but why would Mike mention Novartis unless there is potential for this? Hmmm... IPF is the small molecule that Samumed licensed to United. Samumed is the most highest valued private biotech company in the world currently.
|
|
|
Post by mnkdfann on Oct 31, 2018 12:28:48 GMT -5
Anyone who listened to the call, if the future is so shiny why is UTHR dropping 7% on a day when the markets overall are surging?
Are people just selling UTHR on the news, or did guidance disappoint?
|
|
|
Post by mannmade on Oct 31, 2018 12:31:12 GMT -5
It’s the MannKind connection... just kidding!!!😂😂😂. Happy Halloween and GLTAL’s!!!
|
|
|
Post by figglebird on Oct 31, 2018 12:37:47 GMT -5
I don't believe it's that black and white they are entering a period of time where they both need to execute on mitigating generics through Acquisitions like steadymed and Partnerships like MannKind as well as Branch out into new areas of treatnent that have never yielded revenue for them as a company.
CEO was pretty matter of fact regarding the company's ability to not only maintain the current population with respect to pah treatments but continue to capture the new cases.
As an emerging Growth Company it's hard to see why they would go up if there Revenue is decreasing even if they beat estimates on both earnings and Top Line.
I could see initial investors taking profit off the table at this time while not liquidating their entire positions -they don't exactly trade like MannKind.
|
|
|
Post by itellthefuture777 on Oct 31, 2018 13:41:41 GMT -5
UTHR down 7.77% who could know that..cowinkadink..
|
|
|
Post by itellthefuture777 on Oct 31, 2018 13:49:15 GMT -5
UTHR down 7.77% who could know that..cowinkadink.. If I had to guess..they sell some of that..buy some of this..
|
|
|
Post by kite on Oct 31, 2018 13:53:20 GMT -5
UTHR down 7.77% who could know that..cowinkadink.. If I had to guess..they sell some of that..buy some of this.. I like your thinking
|
|
|
Post by lsl428 on Oct 31, 2018 14:00:49 GMT -5
You know what's weird...market cap on UTHR is now just under 5 billion..... just 4 short years ago right after sanofi partnership announcement ours spiked to 6 billionish ... and at one time UTHR market cap was 250 million .... when this whole thing gets figured out I think we catch and hopefully surpass them
|
|
|
Post by peppy on Oct 31, 2018 14:11:41 GMT -5
Anyone who listened to the call, if the future is so shiny why is UTHR dropping 7% on a day when the markets overall are surging? Are people just selling UTHR on the news, or did guidance disappoint? almost every stock has been selling off after earnings the last couple of months. they bounce up a few days later. UTHR has a fair amount of collaborations.
|
|
|
Post by awesomo on Oct 31, 2018 14:16:59 GMT -5
UTHR's actual numbers were not good: revenue down YoY, Remodulin sales down, cost of product sales way up, etc. Whether these collaborations pan out into actual earnings is yet to be determined. Of course, for our sake, we hope the MannKind collaboration is extremely successful.
|
|
|
Post by peppy on Oct 31, 2018 14:29:23 GMT -5
|
|
|
Post by agedhippie on Oct 31, 2018 15:25:03 GMT -5
The transcript from the call is up on Seeking Alpha. I am probably a bit slow, but I hadn't realize that the device used was bluetooth linked. It sounds like they will be using a variant of Bluehale. I would love to know if the same device will be used for Afrezza once it is approved for UTHR. That could then link into the coaching platforms (One Drop, Onduo, etc.)
|
|